Cargando…

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimagin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermunt, Lisa, van Paasen, Alegría J.L., Teunissen, Charlotte E., Scheltens, Philip, Visser, Pieter Jelle, Tijms, Betty M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556092/ https://www.ncbi.nlm.nih.gov/pubmed/31068481 http://dx.doi.org/10.1212/WNL.0000000000007609

Ejemplares similares

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
por: Tomassen, Jori, et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
por: Gogishvili, Dea, et al.
Publicado: (2023)

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
por: Weiner, Sophia, et al.
Publicado: (2022)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
por: Poil, Simon-Shlomo, et al.
Publicado: (2013)

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
por: Bertens, Daniela, et al.
Publicado: (2019)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging()
por: Nir, Talia M., et al.
Publicado: (2013)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Language Differences Among Individuals with Normal Cognition, Amnestic and Non-Amnestic MCI, and Alzheimer’s Disease
por: Liampas, Ioannis, et al.
Publicado: (2022)

Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years
por: Legdeur, Nienke, et al.
Publicado: (2019)

Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2015)

Direction of Information Flow in Alzheimer's Disease and MCI Patients
por: Vecchio, Fabrizio, et al.
Publicado: (2011)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018)

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
por: den Haan, Jurre, et al.
Publicado: (2019)

Progression to AIDS in South Africa Is Associated with both Reverting and Compensatory Viral Mutations
por: Huang, Kuan-Hsiang Gary, et al.
Publicado: (2011)

Sudden post-traumatic sensorineural hearing loss reverted to normal by sneezing
por: Yenigun, Alper
Publicado: (2014)

The plasma peptides of Alzheimer’s disease
por: Florentinus-Mefailoski, Angelique, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sj4chafm54ondr13c4qb438g1n